Mankind Pharma’s web revenue climbed 9.5% within the third quarter, lacking estimates, as income elevated, pushed by home development and consolidation of Bharat Serums and Vaccines Ltd (BSV), which it acquired in 2024.
The drugmaker’s revenue rose to ₹414 crore within the three months ended December from ₹378 crore a 12 months earlier, the corporate stated in an announcement on Tuesday. Revenue declined 20.4% sequentially. Income grew to ₹3,567 crore.
A Bloomberg ballot of 10 brokerages pegged Mankind’s web revenue at ₹507 crore and income at ₹3,607 crore. Ebitda was little modified at ₹816 crore on-year, whereas the adjusted Ebitda margin contracted by 170 foundation factors to 25.9%.
“BSV development initiatives are progressing nicely, with robust double-digit development in Q3,” vice chairman and managing director Rajeev Juneja stated within the assertion.
Mankind acquired a 100% stake in BSV for ₹13,768 crore in October 2024, giving the generic drugmaker entry into super-specialty, high-entry-barrier merchandise in girls’s well being, fertility and important care.
“We stay assured of delivering long-term sustainable development anchored by 4 key pillars–regular base enterprise, fast-growing specialty persistent, high-potential OTC enterpriseand tremendous specialty BSV portfolio,” Juneja stated.
Analysts anticipated Mankind’s home enterprise to develop on the again of a gradual restoration in its base enterprise after the corporate took corrective measures in FY25, together with management adjustments and improved synergies between divisions.
Persistent medicine
The corporate has been centered on rising the share of its persistent drug portfolio in general gross sales. In Q3, the share of its persistent medicine elevated by 200 foundation factors to 39.3%, pushed by development of 16.7% in cardiac medicine and 14.4% in anti-diabetes medicines, the corporate stated.
Mankind’s home branded medicine enterprise makes up the most important chunk of its general gross sales and expanded 11.1% y-o-y to ₹3,046 crore.
Its shopper well being enterprise grew 5.2% y-o-y to ₹203 crore, regaining momentum after a dip in Q2FY26. “We count on development to enhance additional,” stated Juneja.
Mankind Pharma’s shares gained 4.3% to ₹2,155.90 on the shut on the BSE on Tuesday. This got here amid a broader market surge following the announcement of the India-US commerce dealwith the Nifty Pharma index up 3.02%.